First U.S. NASH/MASH approval + 12 updates...👇
Madrigal Pharmaceuticals
🎯 FDA Approved Rezdiffra™ (resmetirom) for the treatment of NASH (MASH) w/ moderate to advanced liver fibrosis.
Regeneron
🎯 FDA approved Praluent® (alirocumab) injection treating children with genetic form of high cholesterol.
Mirum Pharma
🎯 LIVMARLI received FDA approval for the treatment of cholestatic pruritus in patients w/ progressive familial intrahepatic cholestasis.
BeiGene
🎯 FDA approved TEVIMBRA® treating esophageal squamous cell carcinoma after prior chemotherapy.
Bristol Myers Squibb
🎯 Received FDA approval for Breyanzi® as the first and only CAR-T cell therapy for adults with r/r CLL or SLL.
Geron
🎯 FDA Onco-drugs AdCom votes 12-2 in favor of Imetelstat treating transfusion-dependent anemia in patients with lower-risk MDS.
Aquestive Therapeutics
🔬 Anaphylm™ (epinephrine) sublingual film met primary and secondary endpoints in pivotal Ph3 study.
Acadia Pharmaceuticals
🔬 Top-line results reported from Ph3 ADVANCE-2 trial of Pimavanserin in negative symptoms of schizophrenia.
MitoCareX
🔬 Promising results with the discovery of novel anti-cancer small molecule structure.
Merck & Harpoon Therapeutics
🤝 Merck completed the acquisition of Harpoon Therapeutics
AstraZeneca & Amolyt
🤝 AstraZeneca will acquire Amolyt to expand its late-stage rare disease pipeline.
Aeterna Zentaris & Ceapro
🤝 Merger approved by security holders.
---
Interested in these updates? Get the full update each week → https://www.biopharmiq.com/#subscribe
Data:
March 11-15, 2024
Article History:
RF, DV (03/15/24)
Comments